Wednesday, July 8, 2026

Patent directory · USPTO A61K / A61P

Patents matching “progesterone”

32 pharma patents match "progesterone" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 32
Index total 30,257
Page 1 / 2

Quick answer

This filtered view shows 32 pharmaceutical patents matching "progesterone" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

32 results for “progesterone” · 30,257 patents in full index Clear search

  1. US 11865179

    Progesterone formulations having a desirable PK profile

    Compass Therapeutics LLC · Granted Jan 9, 2024 · Expires Jan 4, 2044

    granted
  2. US 11135154

    Medroxyprogesterone acetate injectable compositions and methods of use

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Oct 5, 2021 · Expires Sep 30, 2041

    granted
  3. US 11033626

    Progesterone formulations having a desirable pk profile

    Compass Therapeutics LLC · Granted Jun 15, 2021 · Expires Jun 10, 2041

    granted
  4. US 10942183

    Methods of detecting progesterone receptor and of detecting an expression level

    Regents of the University of Minnesota · Granted Mar 9, 2021 · Expires Mar 4, 2041

    granted
  5. US 10639375

    Progesterone formulations

    Compass Therapeutics LLC · Granted May 5, 2020 · Expires Apr 30, 2040

    granted
  6. US 10471148

    Progesterone formulations having a desirable PK profile

    Compass Therapeutics LLC · Granted Nov 12, 2019 · Expires Nov 7, 2039

    granted
  7. US 10052386

    Progesterone formulations

    Compass Therapeutics LLC · Granted Aug 21, 2018 · Expires Aug 16, 2038

    granted
  8. US 8663681

    Oral dosage forms comprising progesterone and methods of making and using the same

    TEVA WOMEN'S HEALTH, INC. · Granted Mar 4, 2014 · Expires Feb 27, 2034

    granted
  9. US 8580293

    Monolithic intravaginal rings comprising progesterone and methods of making and uses thereof

    TEVA WOMEN'S HEALTH, INC. · Granted Nov 12, 2013 · Expires Nov 7, 2033

    granted
  10. US 8003629

    21-substituted progesterone derivatives as new antiprogestational agents

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Aug 23, 2011 · Expires Aug 18, 2031

    granted
  11. US 7759330

    21-substituted progesterone derivatives as new antiprogestational agents

    The United States of America, as represented by the Department of Health and Human Services · Granted Jul 20, 2010 · Expires Jul 15, 2030

    granted
  12. US 7723300

    Regulators of the non-genomic action of progesterone and methods of use

    UNIVERSITY OF CONNECTICUT · Granted May 25, 2010 · Expires May 20, 2030

    granted
  13. US 7696246

    Bicyclic androgen and progesterone receptor modulator compounds and methods

    Ligand Pharmaceuticals Incorporated · Granted Apr 13, 2010 · Expires Apr 8, 2030

    granted
  14. US 7163946

    5-substituted 7,9-difluoro-5H-chromeno[3,4-f]quinoline compounds as selective progesterone receptor modulator compounds

    Ligand Pharmaceuticals Incorporated · Granted Jan 16, 2007 · Expires Jan 11, 2027

    granted
  15. US 7087591

    21-substituted progesterone derivatives as new antiprogestational agents

    The United States of America, as represented by the Department of Health and Human Services · Granted Aug 8, 2006 · Expires Aug 3, 2026

    granted
  16. US 7084151

    5-(1',1'-cycloalkyl/alkenyl)methylidene 1,2-dihydro-5H-chromeno[3,4-ƒ]quinolines as selective progesterone receptor modulator compounds

    Ligand Pharmaceuticals Incorporated · Granted Aug 1, 2006 · Expires Jul 27, 2026

    granted
  17. US 7081457

    Cyclothiocarbamate derivatives as progesterone receptor modulators

    Ligand Pharmaceuticals Incorporated · Granted Jul 25, 2006 · Expires Jul 20, 2026

    granted
  18. US 7071205

    5-cycloalkenyl 5H-chromeno[3,4-f]quinoline derivatives as selective progesterone receptor modulator compounds

    Ligand Pharmaceuticals Incorporated · Granted Jul 4, 2006 · Expires Jun 29, 2026

    granted
  19. US 6964973

    Bicyclic androgen and progesterone receptor modulator compounds and methods

    Ligand Pharmaceuticals Incorporated · Granted Nov 15, 2005 · Expires Nov 10, 2025

    expired
  20. US 6861415

    21-substituted progesterone derivatives as new antiprogestational agents

    The United States of America, as represented by the Department of Health and Human Services · Granted Mar 1, 2005 · Expires Feb 24, 2025

    expired
  21. US 6759408

    Combination regimens using progesterone receptor modulators

    Ligand Pharmaceuticals Incorporated · Granted Jul 6, 2004 · Expires Jul 1, 2024

    expired
  22. US 6713478

    Cyclocarbamate derivatives as progesterone receptor modulators

    Ligand Pharmaceuticals Incorporated · Granted Mar 30, 2004 · Expires Mar 25, 2024

    expired
  23. US 6693103

    1,2,3,4-tetrahydro-2-thioxo-quinolinyl and 1,2,3,4-tetrahydro-2-oxo-quinolinyl derivatives as progesterone receptor modulators

    Ligand Pharmaceuticals Incorporated · Granted Feb 17, 2004 · Expires Feb 12, 2024

    expired
  24. US 6566358

    Cyclocarbamate derivatives as progesterone receptor modulators

    Ligand Pharmaceuticals Incorporated · Granted May 20, 2003 · Expires May 15, 2023

    expired